Non ci sono recensioni
Environmental Factors in the Epidemiology of Inflammatory Bowel Disease
Pages 3-20
This new edition is a unique combined resource for physicians and scientists addressing the needs of both groups. In addition to stimulating exchange and collaboration and shortening the path between discovery and application of new knowledge, the book helps clinicians understand new therapeutic concepts from their origins. The volume serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, ultrasound, and endomicroscopy, as well as conventional and complex immunomodulatory principles. The latest edition also includes revised chapters from the previous edition, as well as new chapters reflecting current developments in the field.
Written by experts in their field, Crohn’s Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Second Edition is of great value to gastroenterologists, surgeons, internists, pediatricians and gynecologists trainees, as well as all those involved in Crohn’s disease, ulcerative colitis, and related autoimmune disorders.
Environmental Factors in the Epidemiology of Inflammatory Bowel Disease
Pages 3-20
Role of the Intestinal Immune System in Health
Pages 23-56
Understanding the Epithelial Barrier in IBD
Pages 57-66
Intestinal Microbiology and Ecology in Crohn’s Disease and Ulcerative Colitis
Pages 67-74
The Immune System in IBD: Antimicrobial Peptides
Pages 75-86
Vascular Responses to Intestinal Inflammation
Pages 87-92
Immunobiology of Human Dendritic Cells in Inflammatory Bowel Disease
Pages 93-100
Immunobiology of T-Cells in Inflammatory Bowel Disease
Pages 101-109
Immunobiology of B Cells in Inflammatory Bowel Disease
Pages 111-117
Immune Cells: Monocytes and Macrophages
Pages 119-122
Immune Functions of Epithelial Cells in Inflammatory Bowel Disease
Pages 123-129
Autophagy and Endoplasmic Reticulum Stress
Pages 131-134
Matrix Metalloproteinases
Pages 135-140
Paradigm of T Cell Differentiation in IBD
Pages 141-148
Mouse Models of Chronic Intestinal Inflammation: Characterization and Use in Pharmacological Intervention Studies
Pages 149-165
Stem Cells and Organoids to Study Epithelial Cell Biology in IBD
Pages 167-172
Enhanced Endoscopy
Pages 175-183
Magnetic Resonance Enterography
Pages 185-203
Computed Tomography Enterography and Inflammatory Bowel Disease
Pages 205-215
Ultrasound in Inflammatory Bowel Disease
Pages 217-231
Laboratory Evaluation, Including Novel Diagnostic Markers
Pages 233-242
Pathology of Inflammatory Bowel Disease
Pages 243-258
Objective Assessment of Clinical Disease Activity
Pages 259-266
Objective Assessment of Endoscopic Disease Activity and Mucosal Healing
Pages 267-277
Evaluation of Quality of Life in Crohn’s Disease and Ulcerative Colitis: What Is Health-Related Quality of Life?
Pages 279-289
Evaluation of Health Economics in Inflammatory Bowel Disease
Pages 291-297
The Natural History of Inflammatory Bowel Disease
Pages 301-309
Conventional Medical Management of Crohn’s Disease: Sulfasalazine
Pages 311-314
Steroid Therapy for Crohn’s Disease
Pages 315-319
Thiopurines in Crohn’s Disease
Pages 321-331
Conventional Medical Management of Crohn’s Disease: Methotrexate
Pages 333-342
Adalimumab for the Treatment of Crohn’s Disease
Pages 343-349
Biologic Therapy of Crohn’s Disease: Certolizumab
Pages 351-356
Biologic Therapy for Crohn’s Disease: Infliximab
Pages 357-365
Briakinumab and Ustekinumab: Anti-p40 Antibodies for Inflammatory Bowel Disease Treatment
Pages 367-373
Biological Therapy of Crohn’s Disease: Natalizumab, Vedolizumab, and Anti-MadCAM
Pages 375-380
Optimal Management of Fistulizing Crohn’s Disease
Pages 381-386
Sulfasalazine and 5-Aminosalicylates for Ulcerative Colitis
Pages 389-397
Conventional Therapy of Ulcerative Colitis: Corticosteroids
Pages 399-412
Medical Management of Ulcerative Colitis: Conventional Therapy—Azathioprine
Pages 413-419
Calcineurin Inhibitors in Ulcerative Colitis
Pages 421-428
Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab
Pages 429-433
Biologic Therapy of Ulcerative Colitis: Adalimumab
Pages 435-439
Biologic Therapy of Ulcerative Colitis: Golimumab
Pages 441-448
Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rHUMab Beta 7), Anti-MAdCAM
Pages 449-454
Probiotics, Prebiotics, and Antibiotics in IBD
Pages 455-469
Biosimilars in the Treatment of Inflammatory Bowel Disease
Pages 471-479
Step-Up vs. Top-Down Approach in Crohn’s Disease
Pages 481-489
Leukocytapheresis Therapy of Inflammatory Bowel Disease
Pages 491-504
Surgical Management of Crohn’s Disease and Ulcerative Colitis
Pages 505-517
Extraintestinal Manifestations: Autoimmune Hepatitis
Pages 521-529
Primary Sclerosing Cholangitis
Pages 531-547
Autoimmune Pancreatitis and Other Organ Involvement
Pages 549-556
Cutaneous and Oral Manifestations of Inflammatory Bowel Disease
Pages 557-569
Arthritis, Arthropathy, and Osteoporosis in Inflammatory Bowel Disease
Pages 571-583
Nutrition in Inflammatory Bowel Disease
Pages 587-596
Pregnancy and Fertility in Inflammatory Bowel Disease
Pages 599-607
Pediatric Aspects of Inflammatory Bowel Disease
Pages 609-617
Management and Prevention of Infectious Diseases in IBD Patients
Pages 621-638
Incidence of Cancer and Screening in Inflammatory Bowel Disease
Pages 639-652
Inflammatory Bowel Diseases: How to Identify High-Risk Patients
Pages 653-660
Patient Perspective on Inflammatory Bowel Disease
Pages 663-665
Patient Resources in Inflammatory Bowel Disease
Pages 667-672
Sei sicuro di voler eseguire questa azione?